OBJECTIVE: To reverse the profile of abnormal intracortical excitability in patients with ALS by administering drugs that promote GABAergic transmission. BACKGROUND: Transcranial magnetic stimulation (TMS) has revealed abnormalities of cortical inhibition in ALS, a reduction of the silent period, and the absence of intracortical inhibition normally occurring in response to paired TMS. Impaired inhibitory transmission could play a role in the physiopathology of this illness. METHODS: Using paired TMS with conditioning stimuli from 1-to-6-msec-interstimulus intervals, we investigated 16 patients with ALS. The protocol included: (1) the "drug-free" profile of paired TMS; (2) paired TMS 30 minutes after the intake of diazepam (3.5 mg); (3) paired TMS after 3 weeks' treatment with gabapentin (GBP) (600 mg/day) or riluzole (50 mg/twice a day). RESULTS: Intracortical inhibition is lost in patients with ALS, and this abnormal profile is reversed by diazepam or sustained treatment with GBP. We also noted that motor-evoked potential amplitudes to single stimuli increased (p<0.01) after diazepam and GBP. CONCLUSIONS: The demonstration of pharmacologic reversal of hyperexcitability in patients with ALS makes a potentially significant contribution toward understanding the pathophysiology of a disease that has so far eluded an effective cure.
OBJECTIVE: To reverse the profile of abnormal intracortical excitability in patients with ALS by administering drugs that promote GABAergic transmission. BACKGROUND: Transcranial magnetic stimulation (TMS) has revealed abnormalities of cortical inhibition in ALS, a reduction of the silent period, and the absence of intracortical inhibition normally occurring in response to paired TMS. Impaired inhibitory transmission could play a role in the physiopathology of this illness. METHODS: Using paired TMS with conditioning stimuli from 1-to-6-msec-interstimulus intervals, we investigated 16 patients with ALS. The protocol included: (1) the "drug-free" profile of paired TMS; (2) paired TMS 30 minutes after the intake of diazepam (3.5 mg); (3) paired TMS after 3 weeks' treatment with gabapentin (GBP) (600 mg/day) or riluzole (50 mg/twice a day). RESULTS: Intracortical inhibition is lost in patients with ALS, and this abnormal profile is reversed by diazepam or sustained treatment with GBP. We also noted that motor-evoked potential amplitudes to single stimuli increased (p<0.01) after diazepam and GBP. CONCLUSIONS: The demonstration of pharmacologic reversal of hyperexcitability in patients with ALS makes a potentially significant contribution toward understanding the pathophysiology of a disease that has so far eluded an effective cure.
Authors: Andrea Diana; Rita Pillai; Paolo Bongioanni; Aidan G O'Keeffe; Robert G Miller; Dan H Moore Journal: Cochrane Database Syst Rev Date: 2017-01-09
Authors: Diego Centonze; Maria G Palmieri; Laura Boffa; Mariangela Pierantozzi; Paolo Stanzione; Livia Brusa; M Marciani; Alberto Siracusano; Giorgio Bernardi; M Caramia Journal: J Psychiatry Neurosci Date: 2005-03 Impact factor: 6.186
Authors: Sanjay Kalra; Neil R Cashman; Zografos Caramanos; Angela Genge; Douglas L Arnold Journal: AJNR Am J Neuroradiol Date: 2003-03 Impact factor: 3.825
Authors: Alexandra Vaccaro; Arnaud Tauffenberger; Dina Aggad; Guy Rouleau; Pierre Drapeau; J Alex Parker Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240
Authors: Karina D Thielsen; Jakob M Moser; Thomas Schmitt-John; Morten S Jensen; Kimmo Jensen; Mai Marie Holm Journal: PLoS One Date: 2013-12-11 Impact factor: 3.240